Therawis

Therawis is a Munich-based oncology diagnostics company leveraging a theranostic model to integrate novel diagnostic tools with targeted therapies. The company has developed the ELAEXIA® platform, utilizing mass spectrometry and bioinformatics for biomarker discovery, and offers clinical trial support services across Europe. While its primary focus is on diagnostic products like therascreen® PITX2 and ELAEXIA® FITC, Therawis also provides extensive medical affairs and clinical operations services to pharmaceutical partners, positioning itself at the intersection of diagnostics and therapeutic development.

ELAEXIA® platform combining mass spectrometry and bioinformatics (exAI/exID) for biomarker discovery from biological samples like oncosomes.

Therawis competes in the crowded oncology diagnostics space against large IVD companies (e.g., Roche, Qiagen, Agilent) and numerous startups. Its clinical services business competes with global CROs (Contract Research Organizations) and specialized boutique firms, requiring differentiation through deep oncology and European regulatory expertise.